Osteoarthritis
📧 Sign up to get email alerts when something new happens for Osteoarthritis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2021-04-28FDA Approved: ETODOLAC — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Etodolac submitted by Zydus Pharmaceuticals USA Inc.
-
FDA approval · 2021-04-28FDA Approved: MECLOFENAMATE SODIUM — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for meclofenamate sodium from Mylan Pharmaceuticals Inc.
-
FDA approval · 2021-04-28FDA Approved: ETODOLAC — Supplemental Application (Amneal Pharmaceuticals NY LLC)
FDA approved a supplemental application for etodolac from Amneal Pharmaceuticals NY LLC under ANDA 208834.
-
FDA approval · 2021-04-28FDA Approved: ETODOLAC — Supplemental Application (Chartwell RX, LLC)
The FDA has approved a supplemental application for etodolac submitted by Chartwell RX, LLC.
-
FDA approval · 2021-04-28FDA Approved: RELAFEN DS — Supplemental Application (Carwin Pharmaceutical Associates, LLC)
FDA approved a supplemental application for Relafen DS (nabumetone) submitted by Carwin Pharmaceutical Associates, LLC. Nabumetone is used t…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2021-04-28FDA Approved: NABUMETONE — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for Nabumetone submitted by Actavis Pharma, Inc., relating to Nabumetone's approval status.
-
FDA approval · 2021-04-28FDA Approved: IBUPROFEN — Supplemental Application (Major Pharmaceuticals)
The FDA approved Major Pharmaceuticals' ibuprofen supplemental application, finalizing regulatory changes for this product under an ANDA pro…
-
FDA approval · 2021-04-28FDA Approved: NABUMETONE — Supplemental Application (Exelan Pharmaceuticals Inc.)
FDA approved a supplemental application for Nabumetone from Exelan Pharmaceuticals Inc. to modify an aspect of the approved product. This ac…
-
FDA approval · 2021-04-28FDA Approved: TOLMETIN SODIUM — Supplemental Application (Atland Pharmaceuticals, LLC)
The FDA approved a supplemental application for Tolmetin Sodium from Atland Pharmaceuticals, LLC, updating an existing approval.
-
FDA approval · 2021-04-26FDA Approved: DICLOFENAC POTASSIUM — Supplemental Application (Trifluent Pharma LLC)
FDA approved a supplemental application for Diclofenac potassium from Trifluent Pharma LLC as a generic product.
-
FDA approval · 2021-04-26FDA Approved: INDOMETHACIN — Supplemental Application (XLCare Pharmaceuticals Inc.)
The FDA approved a supplemental application for Indomethacin submitted by XLCare Pharmaceuticals Inc. under ANDA 091240.
-
FDA approval · 2021-04-26FDA Approved: ETODOLAC — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for Etodolac from Zydus Pharmaceuticals USA Inc.
-
CLINICAL_TRIALS trial_result · 2021-04-23Clinical Trial Update: Oxford Signature vs. Conventional Global Study [NA]
Clinical trial update for Oxford Signature versus conventional treatment in knee osteoarthritis; study terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2021-04-14Clinical Trial Update: Measuring Gait And Self-Reported Pain In Patients With Osteoarthritis Of The Knee Using Placebo/Oxycodone/Celecoxib. [Phase 4]
Phase 4 trial assessing gait and self-reported pain in knee osteoarthritis treated with placebo, oxycodone, or celecoxib; study terminated w…
-
FDA approval · 2021-03-31FDA Approved: DICLOFENAC SODIUM — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for Diclofenac Sodium from Actavis Pharma, Inc. under ANDA074514. The approval covers an updated for…
-
FDA approval · 2021-03-26FDA Approved: DICLOFENAC SODIUM — Supplemental Application (Oceanside Pharmaceuticals)
FDA approved Oceanside Pharmaceuticals' supplemental application for diclofenac sodium (a generic NSAID).
-
CLINICAL_TRIALS trial_result · 2021-03-22Clinical Trial Update: Tanezumab in Osteoarthritis of the Knee [Phase 3]
Phase 3 trial update for tanezumab in knee osteoarthritis completed (results posted).
-
CLINICAL_TRIALS trial_result · 2021-03-10Clinical Trial Update: Safety Extension Study Of Tanezumab When Administered By Subcutaneous Injection To Patients With Osteoarthritis [Phase 3]
Phase 3 safety extension study of tanezumab given subcutaneous injection in osteoarthritis was terminated; results posted in 2021.
-
FDA approval · 2021-03-04FDA Approved: TAPENTADOL — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for Tapentadol hydrochloride by Hikma Pharmaceuticals USA Inc., resulting in an updated labeling…
-
CLINICAL_TRIALS trial_result · 2021-03-04Clinical Trial Update: Efficacy Study of Condrosulf in the Treatment of Symptomatic OA of the Hand [Phase 3]
A Phase 3 clinical trial evaluating Condrosulf for symptomatic osteoarthrosis of the hand has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2021-03-03Clinical Trial Update: Effect Of Celecoxib On Hip Osteoarthritis (OA) Progression [Phase 3]
Phase 3 trial update for celecoxib in hip osteoarthritis has been terminated.
-
CLINICAL_TRIALS trial_result · 2021-03-03Clinical Trial Update: Low Dose Naltrexone for Chronic Pain From Arthritis [Phase 2]
Phase 2 clinical trial of low-dose naltrexone for chronic pain from arthritis has completed; results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-03-03Clinical Trial Update: Celebrex Total Knee Arthroplasty Study [Phase 4]
Phase 4 clinical trial update for Celebrex in total knee arthroplasty terminated.
-
CLINICAL_TRIALS trial_result · 2021-02-26Clinical Trial Update: Analgesic Efficacy And Safety of Tanezumab Added On To Diclofenac SR In Patients With Osteoarthritis Of The Knee Or Hip [Phase 3]
Phase 3 trial assessing analgesic efficacy and safety of tanezumab added to diclofenac SR in osteoarthritis of the knee or hip; study termin…
-
CLINICAL_TRIALS trial_result · 2021-02-26Clinical Trial Update: Tanezumab in Osteoarthritis Of The Hip [Phase 3]
Phase 3 trial update for tanezumab in osteoarthritis of the hip; study completed with results posted.